SODIUM CHLORIDE INJECTION 0.9% 5 mL ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium chloride injection 0.9% 5 ml ampoule

interpharma pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections - sodium chloride injection bp 0.9% can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

SODIUM CHLORIDE INJECTION 0.9% 10 mL ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium chloride injection 0.9% 10 ml ampoule

interpharma pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections - sodium chloride injection bp 0.9% can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

CYRAMZA ramucirumab 500 mg/50 mL solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

cyramza ramucirumab 500 mg/50 ml solution for intravenous infusion vial

eli lilly australia pty ltd - ramucirumab, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: histidine; histidine hydrochloride monohydrate; water for injections; glycine; sodium chloride; polysorbate 80 - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

CYRAMZA ramucirumab 100 mg/10 mL solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

cyramza ramucirumab 100 mg/10 ml solution for intravenous infusion vial

eli lilly australia pty ltd - ramucirumab, quantity: 100 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; polysorbate 80; glycine; histidine hydrochloride monohydrate; water for injections; histidine - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

0.9% SODIUM CHLORIDE INTRAVENOUS INFUSION BP 0.9% sodium chloride 50 mL intravenous infusion Australia - English - Department of Health (Therapeutic Goods Administration)

0.9% sodium chloride intravenous infusion bp 0.9% sodium chloride 50 ml intravenous infusion

b braun australia pty ltd - sodium chloride, quantity: 0.45 g - injection, solution - excipient ingredients: water for injections - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established. 0.9% sodium chloride injection may also be used for irrigation of wounds and moistening of wound dressings. compound sodium lactate solution is particularly suitable for the replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

Sodium chloride 0.9% infusion 50ml Viaflo bags United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sodium chloride 0.9% infusion 50ml viaflo bags

baxter healthcare ltd - sodium chloride - infusion - 9mg/1ml

Sodium chloride 0.9% infusion 100ml Viaflo bags United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sodium chloride 0.9% infusion 100ml viaflo bags

baxter healthcare ltd - sodium chloride - infusion - 9mg/1ml

B Braun 5% Glucose Intravenous Infusion BP 250 mL Bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b braun 5% glucose intravenous infusion bp 250 ml bottle

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established.

B Braun 5% Glucose Intravenous Infusion BP 100 mL Bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b braun 5% glucose intravenous infusion bp 100 ml bottle

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established.

B BRAUN 0.9% SODIUM CHLORIDE 1000mL injection Australia - English - Department of Health (Therapeutic Goods Administration)

b braun 0.9% sodium chloride 1000ml injection

b braun australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solution may also be used as a solvent for intravenously administered drugs where compatibility has been established.